Lipid compound, liposome, exosome, lipid nanoparticle and drug delivery system
By modifying specific lipid compound groups on the lipid bilayer membrane of liposomes, exosomes and lipid nanoparticles, the problem of insufficient cell fusion is solved and efficient drug delivery and delivery effects are achieved.
Patent Information
- Application Number
- CN202280089894.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2021-11-25
- Filing Date
- 2022-11-25
- Publication Date
- 2024-11-19
AI Technical Summary
The existing liposomes, exosomes and lipid nanoparticles have shortcomings in cell fusion, making it difficult to effectively improve their transmission efficiency in cells.
By designing specific lipid compound groups, including lipid molecules composed of amino acids such as lysine and arginine, it forms ester or amide bonds, and modifyes the lipid bilayer membrane to improve liposomes and exosomes Cell fusion properties with lipid nanoparticles.
It significantly improves the cell fusion of liposomes, exosomes and lipid nanoparticles, achieves efficient drug delivery and antigen delivery, and is suitable for a variety of drug delivery applications including anticancer agents and mRNA.
Smart Images

Figure BDA0004959149750000091 
Figure BDA0004959149750000101 
Figure BDA0004959149750000141
Abstract
Description
Technical Field
[0001] The present invention relates to a lipid compound, a liposome, an exosome, a lipid nanoparticle and a drug delivery system. This application claims priority based on Japanese Patent Application No. 2021-190933 filed in Japan on November 25, 2021, and cites the contents here. Background Art
[0002] Liposomes are capsules with artificial membranes that mimic lipid bilayer membranes. They are about 100 to 200 nm in size and are used in drug delivery systems or cosmetics. They contain DNA, proteins, drugs, etc. in the aqueous phase inside and deliver the contents only to the affected area. Exosomes are vesicles with a lipid bilayer membrane of about 100 nm secreted by cells and are a type of extracellular vesicle. Exosomes function as a communication tool between cells to deliver encapsulated molecules, and therefore have attracted attention as a drug delivery system. Lipid nanoparticles are particles with a diameter of 10 to 1000 nm as the main component of lipids. They are used as drug delivery systems by encapsulating nucleic acid drugs and the like inside them. The main raw materials of lipid nanoparticles are biocompatible lipids such as triglycerides, diglycerides, monoglycerides, fatty acids, steroids, and surfactants. Lipophilic molecules can be encapsulated inside the particles. In addition, the inside is solid.
[0003] Current vaccine research is shifting from conventional vaccines (inactivated or attenuated vaccines) to subunit vaccines (proteins, peptides, DNA, etc.). Subunit vaccines are safer because they deliver only the physiologically active components required to induce the desired immune response. However, since subunit vaccines are very weak immunogens, immunostimulatory molecules called delivery media or adjuvants need to be added to provide protective immunity. Of note as delivery vehicles is peptide amphiphilic micelles (PAMs), which are unique biomaterials in which the vaccine is part of the nanomaterial itself. Since PAMs are modularized, they can be easily modified to provide both vaccine antigens and adjuvants in a single construct. By administering a model antigen epitope (Ovalbumin 319-340-OVABT) and a known molecular adjuvant (2,3-dipalmitoyl-S-glycerylcysteine-Pam2C, etc.) simultaneously, a deeper understanding of the mechanism by which PAMs exert their immunostimulatory effects can be obtained. In addition, it is known that the immunogenicity of the vaccine varies greatly in vitro and in vivo by a specific combination of antigen and adjuvant. These results provide basic design rules that can be used to produce optimal PAM-based vaccine formulations for future disease-specific uses (Non-Patent Document 1).
[0004] Bacterial lipopeptides are strong immunomodulators that activate early host responses after infection and provide an auxiliary effect on the adaptive immune system. These lipopeptides induce signals to cells of the immune system via Toll-like receptor 2 (TLR2)-TLR1 or TLR2-TLR6 heteromers. Previously, triacylated lipopeptides such as synthetic N-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-(R)-cysteine (Pam3)-CSK4 were thought to signal via TLR2-TLR1 heteromers, while diacylated lipopeptides such as macrophage-activating lipopeptides were thought to signal via TLR2-TLR6 heteromers. Diacyl lipopeptides such as macrophage-activating lipopeptide (MALP2) derived from Mycoplasma fermentans and S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-(R)-cysteine (Pam2)-CGNNDESNISFKEK) induce signal transduction via TLR2-TLR6 heteromers (Non-Patent Document 2).
[0005] It is known that by forming a crosslinked body or complex with a membrane permeable peptide rich in arginine (arginine peptide), various cell membrane impermeable physiologically active molecules headed by protein can be delivered into the cell. Through the interaction with the proteoglycans on the cell surface, the arginine peptide can be attracted to the cell surface, and then transferred into the cell by using the two direct permeation pathways of endocytosis and plasma membrane separately. In addition, the introduction pathway varies according to the physical properties, concentration and other conditions of the crosslinked body / complex with the arginine peptide. The intracellular transfer of the arginine peptide realized by endocytosis is also related to the liquid phase endocytosis (macropinocytosis) of actin drive. In the direct permeation of the plasma membrane, the membrane potential plays an important role, and the membrane is promoted to penetrate (non-patent literature 3) by intervening counterion molecules such as pyrene butyrate. Prior art literature Non-patent literature
[0006] Non-patent literature 1: Zhang, Rui et al., "Vaccine Adjuvant Incorporation Strategy Dictates Peptide Amphiphile Micelle Immunostimulatory Capacity", The AAPS Journal, 2018, Vol. 20, Article No. 73. Non-patent document 2: Buwitt-Beckmann, Ute et al., "Toll-like receptor 6-independent signaling by diacylated lipopeptides", European Journal of Immunology, 2005, Vol. 35, pp. 282-289. Non-patent document 3: Shiro Futaki, “Special Issue: Development of Next-Generation Nanomedicine Using Biofunctional Peptides: Intracellular Transfer of Arginine-Rich Membrane-Permeable Peptides,” Biochemistry, Vol. 89, No. 1, 2017, pp. 8-14. Summary of the invention Technical problem to be solved by the invention
[0007] The technical problem of the present invention is to provide a technology capable of improving the cell fusion property of liposomes, exosomes or lipid nanoparticles. Technical solutions for solving technical problems
[0008] The present invention includes the following aspects. [1] A lipid compound having a group represented by the following formula (1): X a X b -(X1 ) p (X 2 ) q -(X 3 X 4 ) r -(OZ) s -···(1) In formula (1): X a and X b Lysine (K) or arginine (R), X a and X b Different from arginine (R); X 1 is one selected from the group consisting of aspartic acid (D), glutamic acid (E), glycine (G), alanine (A), phenylalanine (F), leucine (L), isoleucine (I), cysteine (C), methionine (M), tyrosine (Y), valine (V), threonine (T), serine (S), proline (P), tryptophan (W), asparagine (N) and glutamine (Q), X 2 is one selected from the group consisting of lysine (K), arginine (R), histidine (H), glycine (G), alanine (A), phenylalanine (F), leucine (L), isoleucine (I), cysteine (C), methionine (M), tyrosine (Y), valine (V), threonine (T), serine (S), proline (P), tryptophan (W), asparagine (N) and glutamine (Q), p and q are 0 or 1 respectively, to neutralize (X 1 ) p (X 2 ) q The charge modes are selected from 0 and 1 respectively; X 3 is at least one selected from the group consisting of aspartic acid (D), glutamic acid (E), glycine (G), alanine (A), phenylalanine (F), leucine (L), isoleucine (I), cysteine (C), methionine (M), tyrosine (Y), valine (V), threonine (T), serine (S), proline (P), tryptophan (W), asparagine (N) and glutamine (Q), X 4is at least one selected from the group consisting of lysine (K), arginine (R), histidine (H), glycine (G), alanine (A), phenylalanine (F), leucine (L), isoleucine (I), cysteine (C), methionine (M), tyrosine (Y), valine (V), threonine (T), serine (S), proline (P), tryptophan (W), asparagine (N) and glutamine (Q), X 3 and X 4 To neutralize X 3 X 4 The charge mode is selected, X 3 and X 4 The order can be swapped. r is an integer from 1 to 8; Z is an alkylene group having 2 to 5 carbon atoms, The average value of s is 1 to 50. [2] The lipid compound according to [1], X a X b It is KK, KR or RK. [3] The lipid compound according to [1] or [2], wherein X 3 X 4 It is EK, DK or SG, and r is an integer from 3 to 5. [4] The lipid compound according to any one of [1] to [3], wherein X 1 is G, p=1 and q=0. [5] The lipid compound according to any one of [1] to [4], wherein Z is an ethylene group, and the average value of s is 1 to 10. [6] The lipid compound according to any one of [1] to [5], wherein the lipid compound is formed by an ester bond, a peptide bond or an amide bond between the hydroxyl terminal of the compound represented by the following formula (1') and the carboxyl terminal of the lipid molecule, X a X b -(X 1 ) p (X 2 ) q -(X 3 X 4 ) r -(OZ)s-OH···(1') In formula (1'): X a and X b Lysine (K) or arginine (R), X a and X b Different from arginine (R); X1 is one selected from the group consisting of aspartic acid (D), glutamic acid (E), glycine (G), alanine (A), phenylalanine (F), leucine (L), isoleucine (I), cysteine (C), methionine (M), tyrosine (Y), valine (V), threonine (T), serine (S), proline (P), tryptophan (W), asparagine (N) and glutamine (Q), X 2 is one selected from the group consisting of lysine (K), arginine (R), histidine (H), glycine (G), alanine (A), phenylalanine (F), leucine (L), isoleucine (I), cysteine (C), methionine (M), tyrosine (Y), valine (V), threonine (T), serine (S), proline (P), tryptophan (W), asparagine (N) and glutamine (Q), p and q are 0 or 1 respectively, to neutralize (X 1 ) p (X 2 ) q The charge modes are selected from 0 and 1 respectively; X 3 is at least one selected from the group consisting of aspartic acid (D), glutamic acid (E), glycine (G), alanine (A), phenylalanine (F), leucine (L), isoleucine (I), cysteine (C), methionine (M), tyrosine (Y), valine (V), threonine (T), serine (S), proline (P), tryptophan (W), asparagine (N) and glutamine (Q), X 4 is at least one selected from the group consisting of lysine (K), arginine (R), histidine (H), glycine (G), alanine (A), phenylalanine (F), leucine (L), isoleucine (I), cysteine (C), methionine (M), tyrosine (Y), valine (V), threonine (T), serine (S), proline (P), tryptophan (W), asparagine (N) and glutamine (Q), X 3 and X 4 To neutralize X 3 X 4 The charge mode is selected, X 3 and X 4 The order can be swapped. r is an integer from 1 to 8; Z is an alkylene group having 2 to 5 carbon atoms, The average value of s is 1 to 50. [7] The lipid compound according to [6], wherein the lipid molecule is a lipid molecule formed by an amide bond between a fatty acid and a diaminomonocarboxylic acid. [8] The lipid compound according to [7], wherein the fatty acid is a long-chain fatty acid having 13 to 21 carbon atoms. [9] The lipid compound according to [7] or [8], wherein the fatty acid is at least one selected from the group consisting of myristic acid, palmitic acid, and stearic acid.
[10] The lipid compound according to any one of [7] to [9], wherein the diaminomonocarboxylic acid is lysine (L), ornithine or homolysine.
[11] A liposome whose lipid bilayer membrane contains the lipid compound according to any one of [1] to
[10] .
[12] An exosome whose lipid bilayer membrane contains the lipid compound according to any one of [1] to
[10] .
[13] A lipid nanoparticle, wherein the lipid comprises the lipid compound according to any one of [1] to
[10] .
[14] A drug delivery system using the liposome described in
[11] .
[15] A drug delivery system using the exosomes described in
[12] .
[16] A drug delivery system using the lipid nanoparticles described in
[13] .
[17] The liposome according to
[11] , which is absorbed from the local area or the vicinity of the area to which it is administered.
[18] The liposome according to
[17] , wherein the local area is the eye, muscle, brain or internal organ.
[19] The exosomes according to
[12] , which are absorbed from the local area or the vicinity of the area to which they are administered.
[20] The exosomes according to
[19] , wherein the local part is the eye, muscle, brain or internal organ.
[21] The lipid nanoparticle according to
[13] , which is absorbed by the local area or the vicinity of the area to which it is administered.
[22] The lipid nanoparticle according to
[21] , wherein the local part is the eye, muscle, brain or internal organ. Effects of the Invention
[0009] According to the present invention, a technology capable of improving the cell fusion property of liposomes, exosomes or lipid nanoparticles can be provided. BRIEF DESCRIPTION OF THE DRAWINGS
[0010] Figure 1 This is a diagram illustrating the experimental method. Figure 2 It is a figure which shows the experimental result. Figure 3 This is a diagram illustrating the experimental method. Figure 4 It is a figure which shows the experimental result. Figure 5 This is a diagram illustrating the experimental method. Figure 6 It is a figure which shows the experimental result. Figure 7 This is a diagram illustrating the experimental method. Figure 8 It is a figure which shows the experimental result. Fig. 9 This is a diagram illustrating the experimental method. Fig.10 This is a diagram illustrating the experimental method. Fig.11 It is a figure which shows the experimental result. Fig.12 This is a diagram illustrating the experimental method. Fig.13 It is a figure which shows the experimental result. Fig.14 This is a diagram illustrating the experimental method. Fig.15 It is a figure which shows the experimental result. Fig.16 This is a diagram illustrating the experimental method. Fig.17 It is a figure which shows the experimental result. Fig.18 This is a diagram illustrating the experimental method. Fig.19 It is a figure which shows the experimental result. Fig. 20 It is a figure which shows the experimental result. DETAILED DESCRIPTION
[0011] Hereinafter, an embodiment of the present invention will be described. However, the embodiment described below is merely an example, and the embodiment of the present invention can be modified in various ways without departing from the gist of the present invention.
[0012] [Lipid compounds] The lipid compound of the present invention has a group represented by the following formula (1). X a X b -(X 1 ) p (X 2 ) q -(X 3 X 4 ) r -(OZ) s -···(1)The meanings of the symbols in formula (1) are as follows.
[0013] X a and X b Lysine (K) or arginine (R), X a and X b Different from arginine (R). X a X b Preferred is KK, KR or RK, more preferred is KK.
[0014] X 1 It is one selected from the group consisting of aspartic acid (D), glutamic acid (E), glycine (G), alanine (A), phenylalanine (F), leucine (L), isoleucine (I), cysteine (C), methionine (M), tyrosine (Y), valine (V), threonine (T), serine (S), proline (P), tryptophan (W), asparagine (N) and glutamine (Q). X 2 It is lysine (K), arginine (R) or histidine (H). p and q are 0 or 1 respectively, to neutralize (X 1 ) p (X 2 ) q The charge modes are selected from 0 and 1 respectively. As (X 1 ) p (X 2 ) q , preferably X 1 is G, p=1 and q=0.
[0015] X 3 is at least one selected from the group consisting of aspartic acid (D), glutamic acid (E), glycine (G), alanine (A), phenylalanine (F), leucine (L), isoleucine (I), cysteine (C), methionine (M), tyrosine (Y), valine (V), threonine (T), serine (S), proline (P), tryptophan (W), asparagine (N) and glutamine (Q), X 4 is at least one selected from the group consisting of lysine (K), arginine (R), histidine (H), glycine (G), alanine (A), phenylalanine (F), leucine (L), isoleucine (I), cysteine (C), methionine (M), tyrosine (Y), valine (V), threonine (T), serine (S), proline (P), tryptophan (W), asparagine (N) and glutamine (Q), X 3 and X 4 To neutralize X3 X 4 The charge mode is selected, X 3 and X 4 The order can be swapped. X 3 X 4 Preferred is EK, DK or SG, more preferred is EK. r is an integer of 1-8, preferably an integer of 3-5, and more preferably 4.
[0016] Z is an alkylene group having 2 to 5 carbon atoms, and is preferably an ethylene group. The average value of s is 1-50, preferably 1-10.
[0017] The lipid compound of the present invention is formed by an ester bond, a peptide bond or an amide bond between the hydroxyl terminal of the compound represented by the following formula (1′) and the carboxyl terminal of a lipid molecule. X a X b -(X 1 ) p (X 2 ) q -(X 3 X 4 ) r -(OZ) s -OH···(1') The meaning of each symbol in formula (1') is the same as the meaning of the same symbol in formula (1).
[0018] The lipid molecule is preferably a lipid molecule formed by amide bonds between fatty acids and diaminomonocarboxylic acids. The fatty acid is preferably a long-chain fatty acid having 13 to 21 carbon atoms, and more preferably at least one selected from the group consisting of myristic acid, palmitic acid, and stearic acid. The diaminomonocarboxylic acid is preferably lysine (L), ornithine or homolysine, and more preferably lysine. The lipid molecule is preferably dipalmitoyl lysine.
[0019] [Liposomes] The liposome of the present invention is a liposome whose lipid bilayer membrane contains the above-mentioned lipid compound. In other words, it is a liposome whose lipid bilayer membrane is modified by the above-mentioned lipid compound. The method for modifying the lipid bilayer membrane of the liposome with the above-mentioned lipid compound is not particularly limited, but preferably a post-modification method (post-insertion method) using a microfluidic device. The post-modification method (post-insertion method) using a microfluidic device not only has excellent high reproducibility and scalability, but also can cope with GMP (Good Manufacturing Practice) manufacturing. In addition, it also has the advantage of not causing significant changes in the physical properties (zeta potential, particle size) of the liposome before modification.
[0020] The liposome of the present invention is preferably absorbed by the part to which it is administered or the vicinity thereof, and more preferably absorbed by the part to which it is administered. The local part includes, but is not limited to, eyes, muscles, joints, bones, brain, abdominal cavity or internal organs. Absorption in the vicinity is not limited to the case of close proximity, and includes, for example, absorption in the internal organs when the drug is administered into the abdominal cavity.
[0021] [Exosomes] The exosomes of the present invention are exosomes whose lipid bilayer membrane contains the above-mentioned lipid compound. In other words, they are exosomes whose lipid bilayer membrane is modified by the above-mentioned lipid compound. The method for modifying the lipid bilayer membrane of the exosome with the above-mentioned lipid compound is not particularly limited, but preferably a post-modification method (post-insertion method) using a microfluidic device. The post-modification method (post-insertion method) using a microfluidic device not only has excellent high reproducibility and scalability, but also can cope with GMP (Good Manufacturing Practice) manufacturing. Moreover, it also has the advantage of not causing significant changes in the physical properties (Zeta potential, particle size, PDI value) of natural exosomes.
[0022] The exosomes of the present invention are preferably absorbed by the local area to which they are administered or the vicinity thereof, and more preferably absorbed by the local area to which they are administered. The local part includes, but is not limited to, eyes, muscles, bones, joints, brain, abdominal cavity or internal organs. Absorption in the vicinity is not limited to the case of close proximity, and includes, for example, absorption in the internal organs when the drug is administered into the abdominal cavity.
[0023] [Lipid Nanoparticles] The lipid nanoparticles of the present invention are lipid nanoparticles whose lipid membranes contain the above-mentioned lipid compounds. In other words, they are lipid nanoparticles whose lipid membranes are modified by the above-mentioned lipid compounds. The method by which the lipid membrane of lipid nanoparticle is modified by the above-mentioned lipid compound is not particularly limited, but is preferably the post-modification method (post-insertion method) using a microfluidic device. The post-modification method (post-insertion method) using a microfluidic device not only has excellent high reproducibility and scalability, but can also cope with GMP (Good Manufacturing Practice) manufacturing. And, there is also the advantage that the physical property (Zeta potential, particle diameter, PDI value) of the lipid nanoparticle before modification will not be greatly changed.
[0024] The lipid nanoparticles of the present invention are preferably absorbed by the part to which they are administered or the vicinity thereof, and more preferably absorbed by the part to which they are administered. The local part includes, but is not limited to, eyes, muscles, joints, bones, brain, abdominal cavity or internal organs. Absorption in the vicinity is not limited to the case of close proximity, and includes, for example, absorption in the internal organs when the drug is administered into the abdominal cavity.
[0025] [Drug delivery system] The drug delivery system of the present invention is characterized by using the above-mentioned liposome, the above-mentioned exosome or the above-mentioned lipid nanoparticle. Since the above-mentioned liposomes, the above-mentioned exosomes or the above-mentioned lipid nanoparticles have high cell fusibility, they can easily and efficiently deliver drugs. For example, the above-mentioned liposomes and the above-mentioned exosomes are suitable for the delivery of highly cytotoxic anticancer agents. In addition, the above-mentioned lipid nanoparticles can be used to improve the delivery efficiency of easily degradable mRNA to target cells.
[0026] In the present invention, “X” in the above formula (1) and formula (1′) may be a X b " is called "functional molecule" and "-(X 1 ) p (X 2 ) q -(X 3 X 4 ) r -(OZ) s -" is called a "spacer". [Example].
[0027] The present invention will be described in more detail below by way of examples. However, the examples described below are merely examples of the present invention and do not limit the present invention.
[0028] [Example 1: Liposome] <Preparation of liposomes> 1. Synthesis of KK-(EK)4-(pal)2 lipid derivatives Various peptide derivatives were synthesized by solid phase synthesis. Deprotection of Fmoc (9-fluorenylmethyloxycarbonyl) was carried out by treatment with 20% piperidine for 20 minutes, and coupling of Fmoc-amino acid was carried out in the presence of HBTU (1-[bis(dimethylamino)methylene]-1H-benzotriazolium 3-hexafluorophosphate oxide) / HOBt (1-hydroxybenzotriazole) / DIPEA (N,N-diisopropylethylamine) for 30 minutes. Unreacted amino groups were acetylated in each step of the synthesis. After coupling of Fmoc-Lys(Fmoc)-OH and deprotection of the Fmoc group, palmitic acid (10 equivalents) was coupled to the amino group of the Lys residue in the presence of HBTU / HOBt / DIPEA. Kaiser test was performed to confirm the completion of the reaction. The lipid was cleaved from the resin by reacting for 3 hours in the presence of TFA (trifluoroacetic acid) / TIS (triisopropylsilane) / H2O (95 / 2.5 / 2.5). The crude product was purified by RP-HPLC, the purity was analyzed, and the molecular weight was confirmed by MALDI-TOF-MS (matrix-assisted laser desorption ionization time-of-flight mass spectrometry).
[0029] 2. Preparation of Liposomes DSPC (1,2-distearoyl-sn-glycero-3-phosphatidylcholine), cholesterol and mPEG 2000 -DSPE (1,2-distearoylphosphatidylethanolamine methyl-bonded polyethylene glycol-2000) (60:35:5, molar ratio) was dissolved in methanol. In addition, 0.5 mol% of rhodamine-DOPE (rhodamine-dioleoyl-phosphatidylethanolamine) was added to label the lipid membrane. After forming a thin film by evaporation, it was placed in a desiccator overnight, then hydrated in sterile water at 65°C, and ultrasonicated for 3 minutes using a probe sonicator. KK-(EK)4 / PEG liposomes were prepared by incubating PEG-modified liposomes with KK-(EK)4 lipid micelles at 60°C for 1 hour. 10× phosphate buffered saline (10×PBS, pH7.4) was added to make the liposomes isotonic, and then filtered through a 0.45μm filter. The particle size, zeta potential, and polydispersity index (PDI) of the prepared liposomes were measured using Zetasizer Nano ZS (manufactured by Malvern Panalytical). Table 1 shows the particle size, zeta potential, and polydispersity index (PDI) of the liposomes.
[0030] [Table 1]
[0031] <Evaluation of liposomes> 1. Evaluation of Cell Fusion of Liposomes Cells were seeded into 24-well plates (2.5 × 10 4 cells / cm 2 ), and after 24 hours, serum-free medium containing 25 μM liposomes was added. After 3 hours of culture, the cells were washed twice with PBS, treated with trypsin, centrifuged (800×g, 25°C, 3 minutes), and resuspended in PBS. The samples were analyzed by LSR Fortessa flow cytometer (manufactured by BD Bioscience).
[0032] 2. Evaluation of Endocytosis Pathways Cells were seeded into 24-well plates (2.5 × 10 4 cells / cm 2 ) and cultured for 24 hours. After culture, the cells were pre-incubated with 0.4M sucrose, 200μM genistein or 50μM 5-(N-ethyl-N-isopropyl)-amiloride (EIPA) at 4°C for 30 minutes. The cells were then incubated with 25μM KK-(EK)4 / PEG liposomes in the presence of inhibitors at 4°C for 30 minutes, washed twice with PBS, recovered by trypsin treatment, centrifuged at 800×g for 3 minutes, and resuspended in PBS. The samples were analyzed by LSR Fortessa flow cytometer (manufactured by BD Bioscience).
[0033] 3. Confocal Laser Microscope Observation Cells were seeded into 35 mm glass dishes (2.5 × 10 4 cells / cm 2 ), and 24 hours later, incubated with serum-free medium containing 25 μM liposomes. After 3 hours, the cells were washed with PBS, incubated with 200 nM LysoTracker Red DND-99 (manufactured by Thermo Fisher Scientific) for 1 hour, and then stained with Hoechst dye (5 μg / mL) for nuclei. The cells were washed with PBS again, placed in medium without phenol red, and observed using an LSM710 confocal microscope (manufactured by Carl Zeiss).
[0034] 4. Study on the influence of spacers (1) Materials Lipid compounds EK-(EK)4-Dipalmitoyl Lysine KK-(EK)4-Dipalmitoyl Lysine KK-(EK)1-Dipalmitoyl Lysine KK-(EK)2-Dipalmitoyllysine KK-(EK)3-Dipalmitoyl Lysine KK-(SG)4-Dipalmitoyl Lysine Liposomes PEGylated liposomes EK-(EK)4 / PEG liposomes KK-(EK)4 / PEG liposomes KK-(EK)1 / PEG liposomes KK-(EK)2 / PEG liposomes KK-(EK)3 / PEG liposomes KK-(SG)4 / PEG liposomes ·cell Human lung cancer cells: A549 cells (2) Methods The experimental method in Figure 1 Shown in. (3) Results The experimental results (evaluation of cell fusion of A549 cells) were Figure 2 Shown in. Compared with PEG liposomes, regardless of the spacer structure, the liposomes showed higher cell fusion properties. Therefore, the sequence representing KK at the front end may be related to the cell fusion properties of the liposomes.
[0035] 5. Study on the influence of functional molecules (1) Materials Lipid compounds EK-(EK)4-Dipalmitoyl Lysine KK-(EK)4-Dipalmitoyl Lysine RK-(EK)4-Dipalmitoyl Lysine KR-(EK)4-Dipalmitoyl Lysine Liposomes PEGylated liposomes EK-(EK)4 / PEG liposomes KK-(EK)4 / PEG liposomes RK-(EK)4 / PEG liposomes KR-(EK)4 / PEG liposomes ·cell Human lung cancer cells: A549 cells (2) Methods The experimental method in Figure 3 Shown in. (3) Results The experimental results (evaluation of cell fusion of A549 cells) were Figure 4 Shown in. Compared with PEG liposomes, all showed higher cell fusion, but the cell fusion of RK-(EK)4 / PEG liposomes showed a lower tendency than the cell fusion of KK-(EK)4 / PEG liposomes and KR-(EK)4 / PEG liposomes. Thus, it is suggested that cell fusion is shown by having two cations at the front end. It is presumed that the large deviation of particle size or polydispersity index (PDI) in the evaluation of physical properties is also one of the reasons why there are differences in the cell fusion of RK-(EK)4 / PEG liposomes.
[0036] 6. Study on the effect of adding a certain amino acid (1) Materials Lipid compounds EK-(EK)4-Dipalmitoyl Lysine KK-(EK)4-Dipalmitoyl Lysine KKG-(EK)4-Dipalmitoyl Lysine Liposomes PEGylated liposomes EK-(EK)4 / PEG liposomes KK-(EK)4 / PEG liposomes KKG-(EK)4 / PEG liposomes ·cell Human lung cancer cells: A549 cells (2) Methods The experimental method in Figure 5 Shown in. (3) Results The experimental results (evaluation of cell fusion of A549 cells) were Figure 6 Shown in. KKG-(EK)4 / PEG liposome showed the same cell fusion property as KK-(EK)4 / PEG liposome, indicating that it is possible to show higher cell fusion property even if amino acids are added between the KK sequence at the front end and the spacer.
[0037] 7. Study on the effect of replacing acidic amino acids (negative amino acids) (1) Materials Lipid compounds EK-(EK)4-Dipalmitoyl Lysine KK-(EK)4-Dipalmitoyl Lysine KK-(DK)4-Dipalmitoyl Lysine Liposomes PEGylated liposomes EK-(EK)4 / PEG liposomes KK-(EK)4 / PEG liposomes KK-(DK)4 / PEG liposomes ·cell Human lung cancer cells: A549 cells (2) Methods The experimental method in Figure 7 Shown in. (3) Results The experimental results (evaluation of cell fusion of A549 cells) were Figure 8 Shown in. KK-(DK)4 / PEG liposomes showed higher cell fusion than PEG liposomes, but showed lower cell fusion than KK-(EK)4 / PEG liposomes. This suggests that even if the same negatively charged amino acid is used, liposomes modified with glutamic acid as the spacer structure also show higher cell fusion.
[0038] [Example 2: Liposome] <Preparation of liposomes> 1. Optimization of KK-(EK)4 structure - preparation of liposomes (1) Materials Lipid compounds KKKK-(EK)4-Dipalmitoyllysine KKK-(EK)4-Dipalmitoyllysine KK-(EK)4-Dipalmitoyl Lysine K-(EK)4-Dipalmitoyllysine EK-(EK)4-Dipalmitoyl Lysine Liposomes Rhodamine labeled liposomes (unmodified liposomes) Lipid composition (molar ratio): DSPC: cholesterol: mPEG-DSPE = 60:35:5, 0.5 mol% rhodamine labeling (2) Methods The experimental method in Fig. 9 Shown in. Furthermore, modification of liposomes with lipid compounds was performed by a post-modification method using a NanoAssemblr nanomedicine fabrication apparatus (manufactured by Precision NanoSystems). The particle size, zeta potential, and polydispersity index (PDI) of the prepared liposomes were measured using Zetasizer Nano ZS (manufactured by Malvern Panalytical). Table 2 shows the particle size, zeta potential, and polydispersity index (PDI) of the liposomes.
[0039] [Table 2]
[0040] <Research on Liposomes> 1. Optimization of KK-(EK)4 structure - Study on the influence of terminal amino acid (1) Materials Lipid compounds KK-(EK)4-Dipalmitoyl Lysine KK-(KE)4-Dipalmitoyl Lysine EK-(EK)4-Dipalmitoyl Lysine KE-(EK)4-Dipalmitoyl Lysine Liposomes Rhodamine labeled liposomes (unmodified liposomes) ·cell Human pancreatic cancer cells: MIAPaca-2 Human lung cancer cells: A549 Mouse colorectal cancer cell line: C26 Mouse fibroblast cell line: NIH3T3 (2) Methods The experimental method in Fig.10 Shown in. Furthermore, modification of liposomes with lipid compounds was performed by a post-modification method using a NanoAssemblr nanomedicine fabrication apparatus (manufactured by Precision NanoSystems). (3) Results The experimental results (evaluation of cell fusion) were Fig.11 Shown in. This suggests that the terminal amino acid KK is beneficial to cell fusion.
[0041] 2. Optimization of KK-(EK)4 structure - Study on the influence of the terminal K number (1) Materials Lipid compounds KKKK-(EK)4-dipalmitoyl lysine (denoted as "K4") KKK-(EK)4-dipalmitoyl lysine (denoted as "K3") KK-(EK)4-dipalmitoyl lysine (denoted as "K2") K-(EK)4-dipalmitoyl lysine (denoted as "K1") Liposomes Rhodamine labeled liposomes (unmodified liposomes) ·cell Mouse colorectal cancer cell line: C26 Mouse fibroblast cell line: NIH3T3 (2) Methods The experimental method in Fig.12 Shown in. Furthermore, modification of liposomes with lipid compounds was performed by a post-modification method using a NanoAssemblr nanomedical fabrication apparatus (manufactured by Precision NanoSystems). (3) Results The experimental results (evaluation of cell fusion) were Fig.13 Shown in. Compared with unmodified liposomes, an increase in cellular uptake was found in the K1, K2, K3, and K4 groups. The uptake of K2 increased in all cells compared to K1, but the uptake of K3 and K4 was the same as that of K2. This suggests that having a K number of 2 or more plays a role in favoring cell fusion. On the other hand, it is thought that positive charges do not seem to play such a favorable role.
[0042] 3. Optimization of KK-(EK)4 structure - Study of terminal amino acids (1) Materials Lipid compounds KK-(EK)4-dipalmitoyl lysine (denoted as "KK-EK") RR-(EK)4-dipalmitoyl lysine (denoted as "RR-EK") EK-(EK)4-dipalmitoyl lysine (referred to as "EK-EK") Liposomes Rhodamine labeled liposomes (unmodified liposomes) ·cell Mouse colorectal cancer cell line: C26 Mouse fibroblast cell line: NIH3T3 (2) Methods The experimental method in Fig.14 Shown in. In addition, the modification of liposomes with lipidic compounds was carried out by a post-modification method using a NanoAssemblr nanomedical production device (manufactured by Precision NanoSystems). (3) The experimental results (evaluation of cell fusion) are shown in Fig.15 . Liposomes were modified with RR-(EK)4 lipid in which the front end of the peptide sequence of KK-(EK)4 lipid was changed to arginine (R) as a cationic amino acid in the same manner as lysine (K), and the cell fusion was compared. The results showed the same cell fusion. Thus, it was revealed that both KK and RR showed the same cell fusion.
[0043] [Example 3: Exosomes] [Preparation of Exosomes] 1. Preparation of KK-(EK)4 / Exosomes Exosomes were labeled with carboxyfluorescein succinimidyl ester (CFSE). After labeling, the protein concentration was measured using a Micro BCA Protein Assay Kit (manufactured by Thermo Fisher Scientific). In the existing post-modification method, KK-(EK)4 lipid micelles and exosome solution were added in a 1:1 ratio by protein mass, and incubated at 37 °C for 1 hour to prepare KK-(EK)4 / exosomes. In the microfluidic device method, KK-(EK)4 lipid micelles and exosome solution were prepared in a 1:1 ratio by protein mass and loaded into a microfluidic chip. The preparation conditions were set as a flow rate ratio of 1:1 and a total flow rate of 1 mL / min. The particle size, Zeta potential, and polydispersity index (PDI) of the prepared samples were measured using a Zetasizer Nano ZS (manufactured by Malvern Panalytical).
[0044] [Evaluation of Exosomes] 1. Evaluation of Cell Fusion of Exosomes Cells were seeded in a 48-well plate (2.5×10 4 cells / cm 2 ). After 24 hours, a serum-free medium containing 5 μg / mL of exosomes was added. After 3 hours, the cells were washed twice with PBS, recovered by trypsin treatment, centrifuged at 800×g for 3 minutes, and resuspended in PBS. This sample was measured using an LSR Fortessa flow cytometer (manufactured by BD Bioscience).
[0045] [Example 4: Lipid Nanoparticles (LNP)] [Preparation of LNP]
[0046] 1. Preparation of KK-(EK)4-Modified mRNA / LNP Dissolve Dlin-MC3-DMA, DSPC, cholesterol, and DSG-PEG 2000 (50:10:38.5:1.5, molar ratio) in ethanol and prepare it to be 15 μg / mL mRNA (in 100 mM citrate buffer). As the mRNA, use mRNA-luciferase encoding firefly luciferase. Load this solution into a microfluidic chip at a flow rate ratio of 1:3 and a total flow rate of 12 mL / min respectively. Place the prepared sample in PBS (pH 7.4) overnight for dialysis. Concentrate the sample by Amicon, measure the particle size and Zeta potential of the LNP using Zetasizer Ultra (manufactured by Malvern Instruments), and measure the encapsulation efficiency of mRNA by RiboGreen detection. Show the particle size, Zeta potential, and mRNA encapsulation efficiency of the liposome in Table 3.
[0047] [Table 3]
[0048] <Evaluation of LNP> 1. In Vitro Luciferase Assay of KK-(EK)4-Modified mRNA / LNP Seed DC2.4 cells into a 48-well plate (4 × 10 4 cells / cm 2 ). After 24 hours, add LNP containing 0.114 μg of mRNA to Complete RPMI medium and culture it with the cells. After 24 hours, wash the cells twice with PBS, treat them with Lysis buffer, and then perform centrifugation (20600 × g, 4 °C, 5 minutes). Measure the supernatant of the sample with a photometer (Luminescencer-PSN, manufactured by ATTO). Further, measure the protein amount using BCA Protein Assays (manufactured by Thermo Fisher Scientific). Show the outline of the experimental method in Fig.16 respectively, and show the experimental results in Fig.17 respectively. In DSG-PEG / LNP, the luciferase expression is maximized at 3 mol% of KK-(EK)4-modified lipid.
[0049] 2. In Vivo Luciferase Assay of KK-(EK)4-Modified mRNA / LNP For ddY mice (male, 4-5 weeks old, Japan SLC, Japan), mRNA / LNP (2 μg mRNA / mouse) was administered into the right hind limb fibular muscle. Bleeding was performed 4.5 hours after administration, and the liver and the right hind limb fibular tendon as the administration site were collected. The collected tissues were washed twice with cold PBS, dissolved in buffer, and homogenized using a homogenizer (Omni Tissue Homogenizer, OMNI international, USA). The tissue homogenate was centrifuged (4°C, 15000×g, 5 minutes) and the supernatant was recovered. The supernatant was added to PicaGene (Toyobo, Japan), and the luciferase activity was measured using a photometer (ATTO-2270, manufactured by ATTO). The data were corrected by using a standard curve made with a luciferase standard solution (Toyobo) and the protein concentration determined by BCA determination. As mRNA / LNP, unmodified mRNA / LNP (abbreviated as "LNP") or 3 mol% KK-(EK)4-modified mRNA / LNP (abbreviated as "KK-modified LNP") was used. The outline of the experimental method is given in Fig.18 The experimental results are shown in Fig.19 (muscle cells) and Fig. 20 (liver cells) are shown. It was confirmed that KK modification resulted in a significant increase in expression in muscle and a significant decrease in expression in liver.
Claims
1. A lipid compound having a group represented by the following formula (1): X a X b -(X 1 ) p (X 2 ) q -(X 3 X 4 ) r -(O-Z) s -···(1) In formula (1): X a and X b Lysine (K) or arginine (R), X a and X b Different from arginine (R); X 1 is one selected from the group consisting of aspartic acid (D), glutamic acid (E), glycine (G), alanine (A), phenylalanine (F), leucine (L), isoleucine (I), cysteine (C), methionine (M), tyrosine (Y), valine (V), threonine (T), serine (S), proline (P), tryptophan (W), asparagine (N) and glutamine (Q), X 2 is one selected from the group consisting of lysine (K), arginine (R), histidine (H), glycine (G), alanine (A), phenylalanine (F), leucine (L), isoleucine (I), cysteine (C), methionine (M), tyrosine (Y), valine (V), threonine (T), serine (S), proline (P), tryptophan (W), asparagine (N) and glutamine (Q), p and q are 0 or 1 respectively, to neutralize (X 1 ) p (X 2 ) q The charge modes are selected from 0 and 1 respectively; X 3 is at least one selected from the group consisting of aspartic acid (D), glutamic acid (E), glycine (G), alanine (A), phenylalanine (F), leucine (L), isoleucine (I), cysteine (C), methionine (M), tyrosine (Y), valine (V), threonine (T), serine (S), proline (P), tryptophan (W), asparagine (N) and glutamine (Q), X 4 is at least one selected from the group consisting of lysine (K), arginine (R), histidine (H), glycine (G), alanine (A), phenylalanine (F), leucine (L), isoleucine (I), cysteine (C), methionine (M), tyrosine (Y), valine (V), threonine (T), serine (S), proline (P), tryptophan (W), asparagine (N) and glutamine (Q), X 3 and X 4 To neutralize X 3 X 4 The charge mode is selected, X 3 and X 4 The order can be swapped. r is an integer from 1 to 8; Z is an alkylene group having 2 to 5 carbon atoms, The average value of s is 1 to 50.
2. The lipid compound according to claim 1, wherein X a X b It is KK, KR or RK.
3. The lipid compound according to claim 1, wherein X 3 X 4 It is EK, DK or SG, and r is an integer from 3 to 5.
4. The lipid compound according to claim 1, wherein X 1 is G, p=1 and q=0.
5. The lipid compound according to claim 1, wherein Z is ethylene, and the average value of s is 1-10.
6. The lipid compound according to claim 1, The hydroxyl terminal of the compound represented by the following formula (1') and the carboxyl terminal of the lipid molecule form an ester bond, a peptide bond or an amide bond, X a X b -(X 1 ) p (X 2 ) q -(X 3 X 4 ) r -(O-Z)s-OH···(1’) In formula (1'): X a and X b Lysine (K) or arginine (R), X a and X b Different from arginine (R); X 1 is one selected from the group consisting of aspartic acid (D), glutamic acid (E), glycine (G), alanine (A), phenylalanine (F), leucine (L), isoleucine (I), cysteine (C), methionine (M), tyrosine (Y), valine (V), threonine (T), serine (S), proline (P), tryptophan (W), asparagine (N) and glutamine (Q), X 2 is one selected from the group consisting of lysine (K), arginine (R), histidine (H), glycine (G), alanine (A), phenylalanine (F), leucine (L), isoleucine (I), cysteine (C), methionine (M), tyrosine (Y), valine (V), threonine (T), serine (S), proline (P), tryptophan (W), asparagine (N) and glutamine (Q), p and q are 0 or 1 respectively, to neutralize (X 1 ) p (X 2 ) q The charge modes are selected from 0 and 1 respectively; X 3 is at least one selected from the group consisting of aspartic acid (D), glutamic acid (E), glycine (G), alanine (A), phenylalanine (F), leucine (L), isoleucine (I), cysteine (C), methionine (M), tyrosine (Y), valine (V), threonine (T), serine (S), proline (P), tryptophan (W), asparagine (N) and glutamine (Q), X 4 is at least one selected from the group consisting of lysine (K), arginine (R), histidine (H), glycine (G), alanine (A), phenylalanine (F), leucine (L), isoleucine (I), cysteine (C), methionine (M), tyrosine (Y), valine (V), threonine (T), serine (S), proline (P), tryptophan (W), asparagine (N) and glutamine (Q), X 3 and X 4 To neutralize X 3 X 4 The charge mode is selected, X 3 and X 4 The order can be swapped. r is an integer from 1 to 8; Z is an alkylene group having 2 to 5 carbon atoms, The average value of s is 1 to 50.
7. The lipid compound according to claim 6, wherein The lipid molecule is a lipid molecule formed by amide bonds between fatty acids and diaminomonocarboxylic acids.
8. The lipid compound according to claim 7, wherein The fatty acid is a long-chain fatty acid having 13 to 21 carbon atoms.
9. The lipid compound according to claim 7, wherein The fatty acid is at least one selected from the group consisting of myristic acid, palmitic acid, and stearic acid.
10. The lipid compound according to claim 7, wherein The diaminomonocarboxylic acid is lysine (L), ornithine or homolysine.
11. A liposome, The lipid bilayer membrane comprises the lipid compound according to any one of claims 1 to 10.
12. An exosome, The lipid bilayer membrane comprises the lipid compound according to any one of claims 1 to 10.
13. A lipid nanoparticle, The lipid comprises the lipid compound according to any one of claims 1 to 10.
14. A drug delivery system, The liposome according to claim 11 is used.
15. A drug delivery system, It uses the exosomes according to claim 12.
16. A drug delivery system, It uses the lipid nanoparticles according to claim 13.
17. The liposome according to claim 11, It is absorbed from or near the site of administration.
18. The liposome according to claim 17, wherein The local part is eyes, muscles, bones, joints, abdominal cavity, brain or internal organs.
19. The exosome according to claim 12, It is absorbed from or near the site of administration.
20. The exosome according to claim 19, wherein The local part is eyes, muscles, bones, joints, abdominal cavity, brain or internal organs.
21. The lipid nanoparticle according to claim 13, It is absorbed from or near the site of administration.
22. The lipid nanoparticle according to claim 21, wherein The local part is eyes, muscles, bones, joints, abdominal cavity, brain or internal organs.
